Melanocortin Research: PT-141, Melanotan II, and the MC Receptor Family

The melanocortin system is a small but powerful receptor family. Five receptors. A handful of endogenous peptide ligands derived from one precursor protein called POMC (proopiomelanocortin). And a structure-activity research history that goes back to the late 1980s.

Two synthetic research peptides dominate the published preclinical literature on this system.

• Melanotan II is a cyclic heptapeptide that acts as a non-selective agonist across multiple melanocortin receptor subtypes
• PT-141, also called bremelanotide, is a structural analogue with preferential activity at MC4R and MC3R

Both came from systematic structure-activity research on the alpha-MSH (alpha-melanocyte-stimulating hormone) backbone in academic medicinal chemistry laboratories.

This article walks through the receptor pharmacology, structural chemistry, and downstream pathway biology characterised in the published research literature.

All discussion is pure receptor pharmacology, third-person research framing, laboratory contexts only.

The melanocortin receptor family

Five class-A G-protein-coupled receptors. Characterised in molecular cloning literature from the early 1990s. Each has a distinct expression pattern.

The five receptors

MC1R Expressed mainly on melanocytes. Principal regulator of eumelanin and pheomelanin synthesis. Couples to G-alpha-s, cAMP elevation, protein kinase A activation.

MC2R Also called the ACTH receptor. Expressed in the adrenal cortex. Selective for ACTH (adrenocorticotropic hormone). The selectivity comes from the requirement for the C-terminal 14 to 24 residues of ACTH, residues that are absent from the other melanocortin peptides.

MC3R Hypothalamus, limbic regions, and certain peripheral tissues. Participates in energy homeostasis and inflammatory pathway regulation.

MC4R The most extensively studied member in CNS research. Expressed in:

• Paraventricular nucleus and arcuate nucleus of the hypothalamus
• Brainstem nuclei
• Spinal cord regions

Characterised as a critical node in feeding behaviour circuitry and in autonomic and central response pathways.

MC5R Exocrine gland tissues, skeletal muscle, certain immune cell populations. MC5R knockout mice display reduced sebum production and altered lacrimal gland function.

Common pharmacophore

All five receptors share a common endogenous ligand framework based on the central His-Phe-Arg-Trp tetrapeptide motif of alpha-MSH and ACTH. But they differ in affinity and efficacy for natural and synthetic agonists characterised in published binding studies.

Receptor structural biology, advanced through published cryo-EM and X-ray crystallography research, has characterised the orthosteric binding pocket and the transmembrane bundle architecture across these subtypes.

Accessory proteins

MRAP (melanocortin receptor accessory protein) is essential for MC2R cell surface expression. MRAP2 modulates MC4R function and participates in the integrated regulation of central melanocortin pathway biology in research models.

Structural chemistry of melanotan II and PT-141

Melanotan II is a cyclic heptapeptide.

Structure: Ac-Nle-cyclo(Asp-His-D-Phe-Arg-Trp-Lys)-NH2

Key structural features

• Lactam bridge between aspartate and lysine side chains, stabilising the bioactive turn structure
• N-acetylation and C-terminal amidation for metabolic stability
• D-phenylalanine substitution at position 7, enhancing receptor binding affinity
• Norleucine substituted for native methionine, eliminating oxidation susceptibility

The cyclic structure adopts a beta-turn conformation that engages the orthosteric binding pocket of melanocortin receptors. The published mutagenesis and structural modelling literature has characterised this engagement as involving the central His-D-Phe-Arg-Trp motif.

PT-141: a linear cousin

PT-141, also called bremelanotide, is structurally derived from melanotan II by cleavage of the C-terminal lysine amide bond. The result is a linear heptapeptide with a free C-terminal carboxylate.

That single structural change alters the receptor selectivity profile. PT-141 shows preferential activity at MC4R and MC3R relative to MC1R, compared to the parent compound.

Why these structures matter

Both molecules display markedly enhanced potency and metabolic stability relative to native alpha-MSH. The published structure-activity research that led to them was foundational in cyclic peptide design at melanocortin receptors.

The transition from the cyclic melanotan II structure to the linear PT-141 structure is a continuation of that work, with the change examined as a means of shifting receptor selectivity and modifying metabolic profile in research models.

Oxytocin is a separate cyclic peptide examined in different pathway research, but it is sometimes included as a comparison compound in published studies of cyclic peptide pharmacology.

Receptor pharmacology and binding profiles

Published receptor pharmacology research has characterised these two molecules in detail.

Melanotan II

Non-selective agonist across MC1R, MC3R, MC4R, and MC5R. High nanomolar to low nanomolar potency at each receptor in heterologous expression systems.

• Little to no activity at MC2R (consistent with MC2R selectivity for ACTH)
• Cyclic structure adopts a beta-turn that engages the orthosteric binding pocket
• Engagement involves the central His-D-Phe-Arg-Trp motif

PT-141

More discriminating receptor profile.

• Preferential activity at MC4R and MC3R
• Measurable but lower activity at MC1R

This selectivity profile distinguishes it from melanotan II and has been the focus of published structure-activity research on linear versus cyclic melanocortin scaffolds.

Full agonism, biased signalling

Both compounds function as full agonists at the receptors they engage in standard cAMP accumulation assays. But published research using beta-arrestin recruitment endpoints has examined biased signalling profiles, with reported differences in relative efficacy at G-protein versus arrestin pathways.

Receptor internalisation

Published research has characterised receptor internalisation kinetics using fluorescently labelled receptors and time-lapse imaging in transfected cell systems.

• Rate of receptor sequestration differs across agonists
• Recycling kinetics differ
• Proportion targeted for lysosomal degradation versus recycled to the cell surface affects sustained pharmacological response

Receptor internalisation is not just a side effect of activation. It is a determinant of the integrated cellular response to repeated or sustained agonist exposure in research models.

Melanogenesis pathway biology

MC1R activation on melanocytes kicks off a well-characterised pathway.

The cAMP cascade

1. Receptor couples to G-alpha-s
2. Intracellular cAMP rises
3. Protein kinase A activates
4. PKA phosphorylates the CREB transcription factor
5. CREB binds the promoter of the MITF gene (microphthalmia-associated transcription factor)
6. MITF activates transcription of melanogenic enzyme genes

The melanogenic enzymes

• Tyrosinase
• Tyrosinase-related protein 1 (TYRP1)
• Dopachrome tautomerase (DCT or TYRP2)

These catalyse the conversion of tyrosine through L-DOPA, dopaquinone, and downstream intermediates to the dark pigment eumelanin.

Eumelanin versus pheomelanin

MC1R signalling also influences the eumelanin-to-pheomelanin ratio.

• Stronger receptor activation favours eumelanin
• Antagonism by the endogenous inverse agonist agouti signalling protein shifts the balance toward pheomelanin

This observation has been characterised in published rodent coat colour genetics research.

MC1R polymorphisms

Natural variation in MC1R sequence across populations and species has been examined in published evolutionary biology research as a model system for understanding how G-protein-coupled receptor variants generate phenotypic diversity. Variant effects on receptor expression, ligand affinity, and downstream signalling have all been characterised.

Melanotan II, as a non-selective melanocortin agonist with significant MC1R activity, has been examined in published preclinical research on melanogenesis pathways. PT-141, with lower relative MC1R activity, engages this pathway less efficiently in published comparative studies.

Central nervous system pathway research

MC4R is a critical node in CNS circuitry. The published neurophysiology literature here is dense.

Where MC4R sits

The receptor is expressed on second-order neurons of the paraventricular hypothalamic nucleus. These neurons receive input from arcuate nucleus POMC neurons.

POMC neuron circuitry

Arcuate nucleus POMC neurons produce alpha-MSH and have been characterised in published neurobiology research as receiving inputs from peripheral metabolic signals including:

• Leptin
• Insulin

They project to multiple downstream brain regions involved in autonomic, neuroendocrine, and behavioural pathway biology.

The opposing AgRP neurons

The arcuate nucleus also contains agouti-related peptide expressing neurons. AgRP acts as an inverse agonist at MC3R and MC4R. The interplay between POMC and AgRP neurons has been characterised as a model system for understanding how GPCR networks integrate competing pathway signals.

MC3R contributions

MC3R, also expressed in the CNS, participates in distinct pathway biology including:

• Modulation of POMC neuron autoinhibition
• Inflammatory signalling

The relative contributions of MC3R and MC4R to integrated central melanocortin pathway function have been the subject of published research using selective pharmacological tools and genetic mouse models lacking individual receptor subtypes.

Brainstem POMC

The brainstem nucleus tractus solitarius also contains POMC-expressing neurons. These participate in autonomic and visceral pathway biology distinct from the arcuate nucleus circuitry.

Autonomic projections from central melanocortin nodes have been examined using anterograde and retrograde tracing in research animals, with characterised projections to sympathetic and parasympathetic preganglionic neurons.

Comparative literature and procurement considerations

Direct comparative research on the two compounds has examined receptor selectivity, pharmacokinetic characteristics, and effects in preclinical CNS pathway biology models.

What the comparison shows

• Melanotan II is the broader-spectrum agonist
• PT-141 shows preferential MC4R and MC3R engagement

The structural relationship (PT-141 derived from melanotan II by C-terminal amide bond cleavage) has been examined as a model system for how minor structural modifications alter receptor selectivity in the melanocortin family.

Analytical characterisation

Standard panel

• Reversed-phase HPLC with ultraviolet detection for purity
• Mass spectrometry for intact-mass confirmation
• Endotoxin testing
• Water content
• Counter-ion quantification

Specific to melanotan II

The lactam bridge integrity is a particular analytical consideration. Ring-opened impurities would alter the receptor pharmacology. Verification by tandem mass spectrometry or chromatographic comparison against reference standards is described in published method literature.

Orthogonal techniques

Published method literature also describes:

• Capillary electrophoresis
• Ion-exchange chromatography
• Circular dichroism spectroscopy

These provide complementary structural and conformational information.

Stability and storage

Both compounds have good aqueous solubility, which simplifies reconstitution compared to lipidated peptides. Careful pH control preserves conformational stability. Attention to the absence of oxidation at the tryptophan residue is important during storage.

Documentation of all analytical results on batch-specific certificates of analysis supports reproducible laboratory characterisation across research groups studying melanocortin pathway biology.

Endogenous ligands and antagonist research

Beyond the synthetic agonists, the endogenous ligand system at melanocortin receptors is extensively characterised.

Agonists from POMC

The POMC precursor is cleaved into several active peptides.

Alpha-MSH 13-residue acetylated peptide. Agonist at MC1R, MC3R, MC4R, and MC5R.

Beta-MSH and gamma-MSH Additional POMC cleavage products with their own receptor selectivity profiles.

ACTH 39-residue peptide. Agonist for MC2R in the adrenal cortex. Engages other melanocortin receptors at higher concentrations in research models.

Endogenous antagonists

Two characterised peptides oppose the agonists.

Agouti signalling protein (ASIP) Inverse agonist at MC1R. Contributes to pigmentation biology characterised in published research on coat colour genetics.

Agouti-related peptide (AgRP) Inverse agonist at MC3R and MC4R. Characterised in research on hypothalamic feeding circuitry.

This regulatory architecture, agonists from POMC versus antagonists from the agouti family, is a model system for understanding the integrated regulation of GPCR systems.

Selective synthetic antagonists

Research tools developed for the melanocortin field include:

• SHU9119
• HS024

Both are MC4R-selective antagonists characterised in published research. They have been used as pharmacological probes to dissect the relative contributions of individual receptor subtypes to integrated pathway biology in standard preclinical assays.

References

1. [1] Mountjoy KG, Robbins LS, Mortrud MT, Cone RD (1992). The cloning of a family of genes that encode the melanocortin receptors. Science. PMID 1325670
2. [2] Hadley ME, Dorr RT (2006). Melanocortin peptide therapeutics: historical milestones, clinical studies and commercialization. Peptides. PMID 16793174
3. [3] Wessells H, Fuciarelli K, Hansen J, et al. (1998). Synthetic melanotropic peptide initiates erections in men with psychogenic erectile dysfunction: double-blind, placebo controlled crossover study. Journal of Urology. PMID 9628737
4. [4] Wikberg JE, Muceniece R, Mandrika I, et al. (2000). New aspects on the melanocortins and their receptors. Pharmacological Research. PMID 10987989
5. [5] Cone RD (2006). Studies on the physiological functions of the melanocortin system. Endocrine Reviews. PMID 16702612
6. [6] Hruby VJ, Cai M, Cain JP, et al. (2007). Design, synthesis and biological evaluation of ligands selective for the melanocortin-3 receptor. Current Topics in Medicinal Chemistry. PMID 17692030

Frequently asked questions